Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Primary Sclerosing Cholangitis Clear all

Conditions: Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, End Stage Liver DIsease, Cirrhosis, Liver
Interventions: Siplizumab; Drug
Lead sponsor: Elizabeth C. Verna; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Sclerosing Cholangitis
Interventions: oral vancomycin and oral amoxicillin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 76 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Primary Sclerosing Cholangitis
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Sclerosing Cholangitis
Interventions: Elafibranor, Placebo; Drug · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 69
States / cities: Chandler, Arizona • Phoenix, Arizona • Coronado, California + 51 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Vidofludimus calcium; Drug
Lead sponsor: Elizabeth Carey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Phoenix, Arizona • Tempe, Arizona • Rochester, Minnesota

Conditions: Primary Sclerosing Cholangitis
Interventions: Hymecromone; Drug
Lead sponsor: Aparna Goel; Other
Eligibility: 14 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Redwood City, California • Stanford, California

Conditions: Primary Sclerosing Cholangitis, PSC, Cholangiocarcinoma
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2035
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Sclerosing Cholangitis
Interventions: PLN-74809, Placebo; Drug
Lead sponsor: Pliant Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Pasadena, California • Redwood City, California • Sacramento, California + 17 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Anti-human CCL24 monoclonal antibody (CM-101), Placebo; Biological · Other
Lead sponsor: ChemomAb Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 8
States / cities: La Jolla, California • Sacramento, California • Chicago, Illinois + 4 more

Conditions: Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions: [18F]FP-R01-MG-F2; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Primary Sclerosing Cholangitis
Interventions: Elafibranor 80 mg, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg, Placebo Matched to Elafibranor 120 mg; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 30
States / cities: Lancaster, California • Los Angeles, California • Sacramento, California + 26 more

Conditions: Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Interventions: TruGraf®; Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: IgG4-related Sclerosing Cholangitis, IgG4-related Disease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: Simtuzumab, Placebo; Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 43
States / cities: Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 34 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Oral Vancomycin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 1 Year and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: LB-P8 low-dose, LB-P8 high-dose, Placebo; Drug
Lead sponsor: LISCure Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Sacramento, California • Aurora, Colorado • Iowa City, Iowa + 4 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Vancomycin, Metronidazole; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Sclerosing Cholangitis
Interventions: Vancomycin, Placebo; Drug · Other
Lead sponsor: Elizabeth Carey; Other
Eligibility: 18 Years to 76 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Phoenix, Arizona • Tempe, Arizona • Jacksonville, Florida + 1 more

Conditions: Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Interventions: No interventions; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 8
States / cities: Palo Alto, California • Indianapolis, Indiana • St Louis, Missouri + 5 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Sulfasalazine, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 15 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Primary Sclerosing Cholangitis
Interventions: BRS201, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Sclerosing Cholangitis
Interventions: Fecal Microbiota Transplantation; Biological
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pruritus
Interventions: EP547, Placebo; Drug
Lead sponsor: Escient Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 17 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Aramchol meglumine; Drug
Lead sponsor: Galmed Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Search by objective public record fields.

A Study of SIPLIZUMAB in AILD and LT Patients

Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC

Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

Vidofludimus Calcium for Primary Sclerosing Cholangitis

Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.

Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

CM-101 in PSC Patients -The SPRING Study

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

TruGraf Liver Gene Expression Serial Test

Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis

Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)

Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis

Vancomycin for Primary Sclerosing Cholangitis

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Detoxification of the Liver In PSC (Dolphin)

Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis